Dianthus Therapeutics (DNTH) Accumulated Depreciation & Amortization (2017 - 2025)
Dianthus Therapeutics has reported Accumulated Depreciation & Amortization over the past 7 years, most recently at $277000.0 for Q3 2025.
- Quarterly results put Accumulated Depreciation & Amortization at $277000.0 for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $277000.0 (changed N/A YoY), and the annual figure for FY2024 was $193000.0, up 98.97%.
- Accumulated Depreciation & Amortization for Q3 2025 was $277000.0 at Dianthus Therapeutics, up from $250000.0 in the prior quarter.
- Over the last five years, Accumulated Depreciation & Amortization for DNTH hit a ceiling of $277000.0 in Q3 2025 and a floor of -$5.9 million in Q4 2022.
- Median Accumulated Depreciation & Amortization over the past 4 years was $193000.0 (2024), compared with a mean of -$1.0 million.
- Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 101.64% in 2023 and later surged 98.97% in 2024.
- Dianthus Therapeutics' Accumulated Depreciation & Amortization stood at -$5.9 million in 2022, then soared by 101.64% to $97000.0 in 2023, then surged by 98.97% to $193000.0 in 2024, then skyrocketed by 43.52% to $277000.0 in 2025.
- The last three reported values for Accumulated Depreciation & Amortization were $277000.0 (Q3 2025), $250000.0 (Q2 2025), and $193000.0 (Q4 2024) per Business Quant data.